Abstract
Universities are particularly vulnerable to infectious disease outbreaks and are also ideal environments to study transmission dynamics and evaluate mitigation and surveillance measures when outbreaks occur. Here, we introduce a SARS-CoV-2 surveillance and response framework based on high-resolution, multimodal data collected during the 2020-2021 academic year at Colorado Mesa University. We analyzed epidemiological and sociobehavioral data (demographics, contact tracing, and wifi-based co-location data) alongside pathogen surveillance data (wastewater, random, and reflexive diagnostic testing; and viral genomic sequencing of wastewater and clinical specimens) to characterize outbreak dynamics and inform policy decisions. We quantified group attributes that increased disease risk, and highlighted parallels between traditional and wifi-based contact tracing. We additionally used clinical and environmental viral sequencing to identify cryptic transmission, cluster overdispersion, and novel lineages or mutations. Ultimately, we used distinct data types to identify information that may help shape institutional policy and to develop a model of pathogen surveillance suitable for the future of outbreak preparedness.
Competing Interest Statement
P.C.S. is a co-founder of, shareholder in, and scientific advisor to Sherlock Biosciences, Inc; she is also a Board member of and shareholder in Danaher Corporation. P.C.S. has filed IP related to genome sequencing and analysis.
Funding Statement
This work was supported by the National Science Foundation (NSF) Graduate Research Fellowship Program to J.S.P. (grant number 1745303), and C.H.T-T. (grant number 1745303); the Hertz Foundation to J.S.P.; the National Institute of General Medical Sciences to B.A.P. (grant number T32GM007753); the National Science Foundation (NSF) to B.C.L. (grant number 2046440); the Moore Foundation to B.C.L., the National Institute of Allergy and Infectious Diseases to B.C.L. (grant number 2U19AI110818) and to P.C.S. (grant number U19AI110818 and U01AI151812); the National Institutes of Health to J.L. (grant numbers R37AI147868 and R01AI148784); the Massachusetts Consortium on Pathogen Readiness to J.L.; the Centers for Disease Control and Prevention (CDC) COVID-19 baseline genomic surveillance contract to the Clinical Research Sequencing Platform (grant number 75D30121C10501) and a CDC Broad Agency Announcement to B.L.M. (grant number 75D30120C09605); and the Howard Hughes Medical Institute to P.C.S. This work was made possible by support from the Flu laboratory and a cohort of generous donors through the TED Audacious Project, including the ELMA Foundation, MacKenzie Scott, Skoll Foundation and Open Philanthropy. Any opinion, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation. This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Massachusetts Institute of Technology gave ethical approval for this work. The Institutional Review Board of the Western IRB-Copernicus Group (WCG) gave ethical approval for this work. The study was conducted at the Broad Institute with approval from the MIT Institutional Review Board under Protocol #1612793224 and from WCG IRB Protocol #20210166 under Protocol: Investigating Viral Emergence and Spread in Community Settings.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All non-identifiable data produced in the present work are contained in the manuscript. Genomic sequences were deposited in NCBI GenBank, GISAID, and the Sequence Read Archive, as applicable.
